Arcutis Stock Is Up 100% in a Year but Here’s Why One Fund Still Sold 1 Million Shares

2 hours ago 1

Jonathan Ponciano, The Motley Fool

Tue, December 23, 2025 astatine 11:38 AM CST 5 min read

New York City-based Suvretta Capital Management sold astir 1.1 cardinal ARQT shares during the 3rd quarter.
The determination contributed to a diminution successful the wide presumption worth by astir $35.78 million.
As of September 30, the money reported holding astir 10.5 cardinal ARQT shares worthy $197.51 million, making it the fund's largest holding.
These 10 stocks could mint the adjacent question of millionaires ›

New York City-based Suvretta Capital Management reported selling astir 1.1 cardinal shares of Arcutis Biotherapeutics (NASDAQ:ARQT) for the 4th ended September 30 and reducing the fund's presumption by $35.78 million.

Suvretta Capital Management disclosed a simplification successful its holding of Arcutis Biotherapeutics (NASDAQ:ARQT), selling astir 1.1 cardinal shares during the 3rd quarter, according to a filing with the Securities and Exchange Commission dated November 14. The determination lowered the involvement to astir 10.48 cardinal shares valued astatine $197.51 cardinal arsenic of September 30. The transaction equates to astir 0.43% of the fund's $3.91 cardinal 13F reportable assets.

Suvretta's ARQT present accounts for 5.06% of 13F AUM and remains the fund’s largest reported holding.

Top holdings aft the filing:

NASDAQ:ARQT: $197.51 cardinal (5.99% of AUM)
NASDAQ:BNTC: $138.57 cardinal (4.20% of AUM)
NASDAQ:META: $125.56 cardinal (3.81% of AUM)
NASDAQ:LEGN: $124.51 cardinal (3.77% of AUM)
NASDAQ:ETNB: $121.72 cardinal (3.69% of AUM)

As of November 13, shares were priced astatine $30.00, up a staggering 100% implicit the past twelvemonth and good outperforming the S&P 500, which is up 15% successful the aforesaid period.

Metric

Value

Price (as of Monday)	$30.00
Market capitalization	$3.67 billion
Revenue (TTM)	$317.93 million
Net income (TTM)	($44.32 million)

Arcutis Biotherapeutics develops and commercializes topical therapies for dermatological diseases, including roflumilast pick and foam for conditions specified arsenic plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.
The institution operates arsenic a biopharmaceutical institution focused connected innovative treatments for tegument disorders.
It serves healthcare providers and patients seeking precocious therapies for chronic dermatological conditions, chiefly successful the United States.

Arcutis Biotherapeutics is dedicated to processing and commercializing topical therapies that code important unmet needs successful dermatology. Its portfolio includes late-stage assets targeting a scope of chronic tegument diseases.

For semipermanent investors, this determination is little astir fading Arcutis and much astir hazard absorption aft a melodramatic re-rating. When a banal doubles successful a year, trimming becomes a portfolio decision, not needfully a cardinal one.

Arcutis precocious reported third-quarter results that reinforced the communicative down the rally. ZORYVE continues to summation traction arsenic the company’s flagship topical franchise, with expanding adoption crossed plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Management has besides been engaged de-risking the pipeline. Since quarter-end, the FDA accepted a supplemental NDA for ZORYVE pick 0.3% successful children ages 2 to 5, with a June 29 people enactment date, and the institution completed enrollment successful its Phase 2 INTEGUMENT-INFANT study. That benignant of regulatory momentum matters for a commercial-stage dermatology institution trying to crook aboriginal occurrence into a durable gross base.

Even aft the sale, Arcutis remains Suvretta’s largest reported holding, good up of names similar Meta and Legend Biotech. That suggests condemnation hasn’t vanished, lone been resized. Ultimately, Arcutis present trades similar a institution with existent expectations baked in, and execution connected pediatric enlargement and sustained medicine maturation volition apt substance much than hype from here.